Know Cancer

or
forgot password

Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients


Phase 0
40 Years
N/A
Not Enrolling
Both
Colorectal, Cancer, Screening, Intervention

Thank you

Trial Information

Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients


First-degree relatives of individuals with CRC are at increased-risk of developing
colorectal cancer (CRC). For these increased-risk individuals current guidelines recommend
initiating CRC screening a decade earlier than for those at average-risk for CRC; thus,
starting at age 40, or 10 years younger than the age at which the affected relative was
diagnosed with CRC. In our prior study of 504 at-risk siblings of patients with a history
of CRC, diagnosed at age less than 56, we found that approximately 44% of these siblings
were not compliant with CRC screening guidelines. Guided by the Transtheoretical, Health
Belief and Dual Process models, our prior study identified key attitudinal and
non-attitudinal predictors of screening behaviors and intentions.

This proposed study will use these results to guide the development and evaluation of
interventions to improve CRC screening acceptance. The proposed study will evaluate the
impact of three interventions to promote CRC screening among siblings in this increased-risk
group, who are not currently compliant with CRC screening guidelines: 1) a generic print
intervention; 2) a tailored print intervention, and; 3) a tailored print plus tailored
telephone counseling intervention.

Siblings in the generic print condition will receive a pamphlet about colorectal cancer
screening published by the Center for Disease Control. Siblings in the tailored print and
telephone counseling conditions will receive messages tailored specifically to their
responses on targeted attitudinal and non-attitudinal measures. Five hundred twenty four
siblings meeting eligibility criteria will be randomly assigned to one of the three
conditions after a baseline interview assessing CRC screening behaviors and attitudes, and
it is anticipated that 427 siblings will complete the study. For siblings in the tailored
conditions, baseline information will be utilized to design the tailored messages. After
receiving the intervention information, participants will be interviewed again six months
later regarding CRC screening behaviors and attitudes to assess the impact of the
intervention.


Inclusion Criteria:



- How old is the participant? (≥ 18 years)

- Is the participant either:

- currently age 40 or above (YES) OR

- within 10 years of the age at which the patient/proband was initially diagnosed with
CRC (whichever is the younger age) (YES)

- Is the participant a full or half biological sibling of the patient/proband? (YES)

Exclusion Criteria:

- Is the participant currently not compliant with standard CRC screening guidelines?
(NO)

- Is the participant English speaking? (YES)

- Does the participant have a primary language other than English? (NO)

- Does the participant have a history of Inflammatory Bowel Disease? (NO)

- Does the participant have a history of colorectal cancer of colorectal polyp? (NO)

- Does the participant have a history of hereditary colorectal cancer syndrome?
(Familial Adenomatous Polyposis or Hereditary Nonpolyposis Colorectal Cancer) (NO)

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Phone follow-up interview. Participants will be contacted by study assistant and the survey administered.

Outcome Time Frame:

6 months after baseling

Safety Issue:

No

Principal Investigator

Arnold Markowitz, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

03-043

NCT ID:

NCT00582829

Start Date:

June 2003

Completion Date:

May 2008

Related Keywords:

  • Colorectal
  • Cancer
  • Screening
  • Intervention
  • Colorectal
  • Cancer
  • Screening
  • Intervention
  • Family
  • Colorectal Neoplasms

Name

Location

Memorial Sloan Kettering Cancer Center New York, New York  10021